Neuronetics, Inc.: Business Overview, Financials & Competitive Analysis
Neuronetics, Inc. scores 5/10 on the AskCyborg Cyborg Score (Mixed). Neuronetics faces profitability headwinds despite solid revenue growth driven by Greenbrook vertical integration, with payer coverage expansion and market expansion providing upside optionality but execution risk remaining. 2024 revenue grew 4.96% to $74.89 million, but losses increased 44.8% to -$43.71 million. Stock has fallen 62.85% over the past 12 months.
What is Neuronetics, Inc.'s industry? Neuronetics, Inc. (neuronetics.com) operates in Medical Devices - Neurohealth/Mental Health Treatment. AskCyborg classifies Neuronetics, Inc. under Medical Devices - Neurohealth/Mental Health Treatment in its company registry.
Neuronetics is a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders. The company's ...
Cyborg Score thesis
Neuronetics faces profitability headwinds despite solid revenue growth driven by Greenbrook vertical integration, with payer...
Read the full analyst-debate transcript →Get the Latest Neuronetics, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeNeuronetics, Inc. Overview
Pro stress-test →Neuronetics is a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders. The company's NeuroStar Advanced Therapy System is a non-invasive, office-based treatment using transcranial magnetic stimulation to create a pulsed magnetic field that stimulates specific brain areas associated with mood. The company operates both as a device manufacturer and through its Greenbrook TMS clinic chain following its strategic acquisition.
Strategic Profile
Pro stress-test →The strategic acquisition of Greenbrook TMS has vertically integrated the company's value chain and positioned it for long-term growth. Neuronetics has secured significant payer coverage expansions, including New York State Medicaid and TRICARE coverage, and has established exclusive partnerships like a three-year collaboration with Elite DNA Behavioral Health to expand NeuroStar TMS access. The company is pursuing market expansion into adolescent care and broadening clinical indications beyond major depressive disorder.
Competitive Landscape
Pro stress-test →STIM operates in the medical devices space with higher volatility (13% weekly) than 75% of US stocks. Primary competition comes from alternative depression treatments including pharmaceutical approaches, other neuromodulation technologies (rTMS competitors), and psychotherapy services. Neuronetics' differentiation stems from its vertically integrated clinic network via Greenbrook, established payer relationships, and FDA clearances across multiple indications including anxious depression and adolescent populations.
Industry Context
Neuronetics, Inc. operates in Medical Devices - Neurohealth/Mental Health Treatment.
Key facts
Founded: 2001 · Headquarters: Malvern, Pennsylvania, USA · Revenue: $149.2M (FY2025 preliminary) · Market cap: $100M